Loading...
•
Jun 30, 2020
Biogen Q2 2020 Earnings Report
Reported strong financial results and completed the BLA submission for aducanumab.
Key Takeaways
Biogen reported Q2 2020 revenues of $3.7 billion, a 2% increase compared to Q2 2019. GAAP diluted EPS increased 22% to $9.59, while Non-GAAP diluted EPS increased 12% to $10.26. The company completed the submission of the BLA for aducanumab in Alzheimer's disease in the U.S.
Total revenues were $3,682 million, a 2% increase versus the second quarter of 2019.
GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $1,542 million and $9.59, respectively.
Non-GAAP net income and diluted EPS attributable to Biogen Inc. were $1,651 million and $10.26, respectively.
Biogen completed the submission of a BLA to the FDA for aducanumab as a treatment for Alzheimer’s disease.
Biogen
Biogen
Biogen Revenue by Segment
Biogen Revenue by Geographic Location
Revenue by Segment
Multiple Sclerosis Revenue
CapyFin.comBiosimilars Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Biogen provided an update to its full year 2020 financial guidance.
Positive Outlook
- Revenue is expected to be approximately $13.8 billion to $14.2 billion.
- GAAP and Non-GAAP R&D expense is expected to be approximately 16% to 17% of total revenues.
- GAAP and Non-GAAP SG&A expense is expected to be approximately 17.5% to 18.5% of total revenues.
- GAAP tax rate is expected to be approximately 18.5% to 19.5%.
- Non-GAAP tax rate is expected to be approximately 18% to 19%.
Challenges Ahead
- GAAP diluted EPS is expected to be between $32.00 and $34.00.
- Non-GAAP diluted EPS is expected to be between $34.00 and $36.00.
- This financial guidance does not include any operational impact from the potential entry of generic versions of TECFIDERA in the U.S. in 2020.
- This financial guidance does not include any impact from potential acquisitions or large business development transactions, as both are hard to predict.
- Biogen may incur charges, realize gains or losses, or experience other events or circumstances in 2020 that could cause actual results to vary from this financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income